Membrane proteins are without a doubt an important drug target: about 60% of all confirmed drug targets are located on the cell surface. However, studying these proteins in vitro has long been challenging due to…
Tackling the Hard-to-Drug Frontier: The Power of Complementary Screening Modalities
Developing small-molecule drugs for hard-to-drug targets remains one of the toughest challenges in modern drug discovery. Targets like cytokines, transcription factors, and scaffolding proteins often lack well-defined…
Isotopic Labeling in Mammalian Expression: The Missing Link for NMR Studies of Hard-to-Express Proteins
ZoBio is excited to introduce a new exclusive capability for making complex protein samples for drug discovery: isotopic labeling during mammalian expression. This ability provides the missing link between…
Using SEC-MALS to Validate BRICHOS Oligomer Structures
The BRICHOS domain is a molecular chaperone known for its ability to prevent amyloid and amorphous protein aggregation, playing a critical role in protecting cells from protein misfolding. ZoBio has an active collaboration with the Karolinska Institutet, where we are exploring the Bri2 BRICHOS…